Importance of long non-coding RNAs in the pathogenesis, diagnosis, and treatment of prostate cancer

GND
1249707153
ORCID
0000-0001-8381-0591
Affiliation
Institute of Human Genetics, Jena University Hospital
Taheri, Mohammad;
Affiliation
Men’s Health and Reproductive Health Research Center, Shahid Beheshti University of Medical Sciences ,Tehran ,Iran
Badrlou, Elham;
Affiliation
Department of Clinical Analysis, College of Pharmacy, Hawler Medical University ,Erbil, Kurdistan ,Iraq
Hussen, Bashdar Mahmud;
Affiliation
Urology and Nephrology Research Center, Shahid Beheshti University of Medical Sciences ,Tehran ,Iran
Kashi, Amir Hossein;
Affiliation
Department of Medical Genetics, School of Medicine, Shahid Beheshti University of Medical Sciences ,Tehran ,Iran
Ghafouri-Fard, Soudeh;
GND
112808337X
ORCID
0000-0003-1085-9161
Affiliation
Institute of Human Genetics, Jena University Hospital
Baniahmad, Aria

Long non-coding RNAs (lncRNAs) are regulatory transcripts with essential roles in the pathogenesis of almost all types of cancers, including prostate cancer. They can act as either oncogenic lncRNAs or tumor suppressor ones in prostate cancer. Small nucleolar RNA host genes are among the mostly assessed oncogenic lncRNAs in this cancer. PCA3 is an example of oncogenic lncRNAs that has been approved as a diagnostic marker in prostate cancer. A number of well-known oncogenic lncRNAs in other cancers such as DANCR, MALAT1, CCAT1, PVT1, TUG1 and NEAT1 have also been shown to act as oncogenes in prostate cancer. On the other hand, LINC00893, LINC01679, MIR22HG, RP1-59D14.5, MAGI2-AS3, NXTAR, FGF14-AS2 and ADAMTS9-AS1 are among lncRNAs that act as tumor suppressors in prostate cancer. LncRNAs can contribute to the pathogenesis of prostate cancer via modulation of androgen receptor (AR) signaling, ubiquitin–proteasome degradation process of AR or other important signaling pathways. The current review summarizes the role of lncRNAs in the evolution of prostate cancer with an especial focus on their importance in design of novel biomarker panels and therapeutic targets.

Cite

Citation style:
Could not load citation form.

Rights

License Holder: Copyright © 2023 Taheri, Badrlou, Hussen, Kashi, Ghafouri-Fard and Baniahmad

Use and reproduction: